{"doi":"10.1111\/j.1475-5890.1998.tb00290.x","coreId":"198347","oai":"oai:eprints.lse.ac.uk:1461","identifiers":["oai:eprints.lse.ac.uk:1461","10.1111\/j.1475-5890.1998.tb00290.x"],"title":"Regulating drug prices: where do we go from here?","authors":["Bloom, Nick","Van Reenen, John"],"enrichments":{"references":[],"documentType":{"type":null}},"contributors":[],"datePublished":"1998-08","abstract":"This paper examines the arguments for changing the ways that UK drug prices are regulated. In the UK, NHS pharmaceutical expenditures on branded drugs, currently worth about \u00a33 billion a year, have been regulated by the Pharmaceutical Price Regulation Scheme (PPRS) since 1978. We argue that, in publicly funded healthcare systems, pharmaceutical price regulation is necessitated by a tendency towards excessive government expenditure because of over-prescription and the monopoly power of firms with on-patent drugs. We briefly explain the operation of the PPRS. which is based on rate-of-return regulation, and discuss its merits and drawbacks. We then consider five alternative pricing systems: free pricing, therapeutic benefit pricing, international reference pricing, therapeutic reference pricing and RPI - X price regulation. However, we reject all these alternatives in favour of a reformed PPRS. We suggest three potential reforms of the PPRS: an RPI - X cost allowance if feasible or a widening of the rate-of-return bands otherwise; the introduction of a marketing innovation allowance; and greater regulatory transparency","downloadUrl":"","fullTextIdentifier":null,"pdfHashValue":null,"publisher":"Wiley-Blackwell on behalf of the Institute for Fiscal Studies","rawRecordXml":"<record><header><identifier>\n    \n    \n      oai:eprints.lse.ac.uk:1461<\/identifier><datestamp>\n      2010-10-01T08:45:23Z<\/datestamp><setSpec>\n      74797065733D434F4C4C53:4C53455F435F454F<\/setSpec><setSpec>\n      74797065733D43454E54524553:4C53455F52435F3131<\/setSpec><\/header><metadata><oai_dc:dc xmlns:oai_dc=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/\" xmlns:dc=\"http:\/\/purl.org\/dc\/elements\/1.1\/\" xmlns:xsi=\"http:\/\/www.w3.org\/2001\/XMLSchema-instance\" xsi:schemaLocation=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/ http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc.xsd\" ><dc:relation>\n    \n      \n        http:\/\/eprints.lse.ac.uk\/1461\/<\/dc:relation><dc:title>\n        Regulating drug prices: where do we go from here?<\/dc:title><dc:creator>\n        Bloom, Nick<\/dc:creator><dc:creator>\n        Van Reenen, John<\/dc:creator><dc:subject>\n        HB Economic Theory<\/dc:subject><dc:subject>\n        RA Public aspects of medicine<\/dc:subject><dc:description>\n        This paper examines the arguments for changing the ways that UK drug prices are regulated. In the UK, NHS pharmaceutical expenditures on branded drugs, currently worth about \u00a33 billion a year, have been regulated by the Pharmaceutical Price Regulation Scheme (PPRS) since 1978. We argue that, in publicly funded healthcare systems, pharmaceutical price regulation is necessitated by a tendency towards excessive government expenditure because of over-prescription and the monopoly power of firms with on-patent drugs. We briefly explain the operation of the PPRS. which is based on rate-of-return regulation, and discuss its merits and drawbacks. We then consider five alternative pricing systems: free pricing, therapeutic benefit pricing, international reference pricing, therapeutic reference pricing and RPI - X price regulation. However, we reject all these alternatives in favour of a reformed PPRS. We suggest three potential reforms of the PPRS: an RPI - X cost allowance if feasible or a widening of the rate-of-return bands otherwise; the introduction of a marketing innovation allowance; and greater regulatory transparency.<\/dc:description><dc:publisher>\n        Wiley-Blackwell on behalf of the Institute for Fiscal Studies<\/dc:publisher><dc:date>\n        1998-08<\/dc:date><dc:type>\n        Article<\/dc:type><dc:type>\n        PeerReviewed<\/dc:type><dc:identifier>\n          Bloom, Nick and Van Reenen, John  (1998) Regulating drug prices: where do we go from here?  Fiscal Studies, 19 (3).  pp. 321-342.  ISSN 0143-5671     <\/dc:identifier><dc:relation>\n        http:\/\/www.wiley.com\/bw\/journal.asp?ref=0143-5671<\/dc:relation><dc:relation>\n        10.1111\/j.1475-5890.1998.tb00290.x<\/dc:relation><\/oai_dc:dc><\/metadata><\/record>","journals":null,"language":null,"relations":["http:\/\/eprints.lse.ac.uk\/1461\/","http:\/\/www.wiley.com\/bw\/journal.asp?ref=0143-5671","10.1111\/j.1475-5890.1998.tb00290.x"],"year":1998,"topics":["HB Economic Theory","RA Public aspects of medicine"],"subject":["Article","PeerReviewed"],"fullText":null}